Trial Profile
An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Masupirdine (Primary)
- Indications Alzheimer's disease
- Focus Expanded access; Therapeutic Use
- Sponsors Suven Life Sciences
- 25 Sep 2020 Status changed from recruiting to completed.
- 28 Jun 2018 New trial record